Quick Takeaways
- MAVERICK CAPITAL LTD filed SCHEDULE 13G for Rocket Pharmaceuticals, Inc. Common Stock, $0.01 par value (RCKT).
- Disclosed ownership: 5.2%.
- Date of event: 07 Apr 2025.
MAVERICK CAPITAL LTD - 07 Apr 2025 SCHEDULE 13G Report for Rocket Pharmaceuticals, Inc. Common Stock, $0.01 par value (RCKT)
- Filing Manager
- MAVERICK CAPITAL LTD
- Reporting Manager
- Maverick Capital, Ltd.
- Symbol
- RCKT
- Shares outstanding
- 106,676,442 shares
- Disclosed Ownership
- 5,547,175 shares
- Ownership
- 5.2%
- Form type
- SCHEDULE 13G
- Filing time
- 14 Apr 2025, 17:10:22 UTC
- Date of event
- 07 Apr 2025
- Next filing
- 14 Aug 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"MAVERICK CAPITAL LTD disclosed 5.2% ownership in Rocket Pharmaceuticals, Inc. Common Stock, $0.01 par value (RCKT) on 07 Apr 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Apr 2025, 17:10.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Maverick Capital, Ltd. | 5.2% | 5,547,175 | 0 | 5,547,175 | /s/ Trevor Wiessmann* | By: Maverick Capital Management, LLC, its General Partner By: Lee S. Ainslie III, Manager | |
| Maverick Capital Management, LLC | 5.2% | 5,547,175 | 0 | 5,547,175 | /s/ Trevor Wiessmann* | Lee S. Ainslie III, Manager | |
| Lee S. Ainslie III | 5.2% | 5,547,175 | 0 | 5,547,175 | /s/ Trevor Wiessmann* | Lee S. Ainslie III |